Identification
NameFlurandrenolide
Accession NumberDB00846  (APRD00982)
TypeSmall Molecule
GroupsApproved
Description

A corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive. (From Martindale, The Extra Pharmacopoeia, 30th ed, p733)

Structure
Thumb
Synonyms
Cordran
Fludrossicortide
Fludroxicortida
Fludroxicortide
Fludroxycortid
Fludroxycortide
Fludroxycortidum
Flurandrenolide
Flurandrenolone
External IDs 33379 / Lilly 33379
Product Ingredients
IngredientUNIICASInChI KeyDetails
Flurandrenolide acetate0P9257GI1B 2802-11-1AUDPKCCPWYXNEV-XTLNBZDDSA-NDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CordranOintment.5 mg/gTopicalAqua Pharmaceuticals1965-10-18Not applicableUs
CordranTape4 ug/cm2TopicalActavis Pharma Company1969-07-29Not applicableUs
CordranCream.5 mg/gTopicalAqua Pharmaceuticals1965-10-18Not applicableUs
CordranLotion.5 mg/mLTopicalAqua Pharmaceuticals1963-03-19Not applicableUs
CordranTape4 ug/cm2TopicalAllergan2016-08-15Not applicableUs
Drenison Tape M 170 4mcg Sq CmTape4 mcgTopicalEli Lilly & Co. Ltd.1969-12-311999-08-11Canada
FlurandrenolideLotion.5 mg/mLTopicalTaro Pharmaceuticals U.S.A., Inc.2016-04-25Not applicableUs
FlurandrenolideCream.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2016-04-25Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FlurandrenolideLotion.5 mg/mLTopicalCintex Services, Llc2016-12-22Not applicableUs
FlurandrenolideCream.5 mg/gTopicalTeligent Pharma, Inc.2016-04-132017-01-06Us
FlurandrenolideOintment.5 mg/gTopicalTeligent Pharma, Inc.2016-12-30Not applicableUs
FlurandrenolideLotion.5 mg/mLTopicalPerrigo New York Inc.2016-10-06Not applicableUs
Flurandrenolide CreamCream.5 mg/gTopicalCintex Services, Llc2016-04-18Not applicableUs
NolixLotion.5 mg/mLTopicalArtesa Labs, Llc2017-05-22Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Cordran SPWatson
DrenisonBiolab
HaelanTypharm Limited
Brand mixturesNot Available
Categories
UNII8EUL29XUQT
CAS number1524-88-5
WeightAverage: 436.5136
Monoisotopic: 436.226116993
Chemical FormulaC24H33FO6
InChI KeyPOPFMWWJOGLOIF-XWCQMRHXSA-N
InChI
InChI=1S/C24H33FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h7,13-14,16-17,19-20,26,28H,5-6,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1
IUPAC Name
(1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-17-en-16-one
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)CC[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO
Pharmacology
Indication

For relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly dry, scaling localized lesions

Structured Indications
Pharmacodynamics

Flurandrenolide is primarily effective because of its anti-inflammatory, antipruritic, and vasoconstrictive actions.

Mechanism of action

Flurandrenolide is a topical corticosteroid. It is normally applied to a plastic tape called Cordran. Cordran is primarily effective because of its anti-inflammatory, antipruritic, and vasoconstrictive actions. Flurandrenolide, which is slowly released from the Cordran tape, binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. Cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In another words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Like other glucocorticoid agents Fluocinolone acetonide acts as a physiological antagonist to insulin by decreasing glycogenesis (formation of glycogen). It also promotes the breakdown of lipids (lipolysis), and proteins, leading to the mobilization of extrahepatic amino acids and ketone bodies. This leads to increased circulating glucose concentrations (in the blood). There is also decreased glycogen formation in the liver.

TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
Absorption

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to those of systemically administered corticosteroids

Volume of distributionNot Available
Protein binding

Corticosteroids are bound to plasma proteins in varying degrees.

Metabolism

Primarily hepatic

Route of elimination

Topical corticosteroids can be absorbed from normal intact skin. They are metabolized primarily in the liver and then excreted in the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Half lifeNot Available
ClearanceNot Available
Toxicity

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary- adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Flurandrenolide.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Flurandrenolide.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Flurandrenolide.Approved
AldesleukinFlurandrenolide may decrease the antineoplastic activities of Aldesleukin.Approved
Aluminum hydroxideThe bioavailability of Flurandrenolide can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Flurandrenolide.Approved
AmiodaroneThe serum concentration of Flurandrenolide can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BFlurandrenolide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Flurandrenolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Flurandrenolide.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Flurandrenolide.Approved
ApocyninThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Flurandrenolide.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Flurandrenolide.Approved, Investigational
AprepitantThe serum concentration of Flurandrenolide can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Flurandrenolide can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Flurandrenolide.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Flurandrenolide.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Flurandrenolide.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Flurandrenolide.Approved, Investigational
BazedoxifeneThe serum concentration of Flurandrenolide can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideFlurandrenolide may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Flurandrenolide.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Flurandrenolide.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Flurandrenolide.Investigational
Bismuth SubcitrateThe bioavailability of Flurandrenolide can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Flurandrenolide can be increased when it is combined with Boceprevir.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Flurandrenolide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Flurandrenolide.Investigational
BumetanideFlurandrenolide may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Flurandrenolide.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Flurandrenolide can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe serum concentration of Flurandrenolide can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Flurandrenolide.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Flurandrenolide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Flurandrenolide.Approved, Investigational
CeritinibFlurandrenolide may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Flurandrenolide.Approved, Vet Approved
ChlorothiazideFlurandrenolide may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Flurandrenolide can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneFlurandrenolide may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Flurandrenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Flurandrenolide.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of Flurandrenolide can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Flurandrenolide.Approved
CobicistatThe serum concentration of Flurandrenolide can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Flurandrenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Flurandrenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Flurandrenolide can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Flurandrenolide.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Flurandrenolide.Investigational
DarunavirThe serum concentration of Flurandrenolide can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Demecarium.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Flurandrenolide.Approved, Vet Approved
DienestrolThe serum concentration of Flurandrenolide can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Flurandrenolide can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flurandrenolide.Approved
DihydrotestosteroneFlurandrenolide may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Flurandrenolide.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Flurandrenolide.Investigational
E-6201The risk or severity of adverse effects can be increased when E6201 is combined with Flurandrenolide.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Flurandrenolide.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Flurandrenolide can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Flurandrenolide.Approved
EquolThe serum concentration of Flurandrenolide can be increased when it is combined with S Equol.Investigational
EstradiolThe serum concentration of Flurandrenolide can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Flurandrenolide can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Flurandrenolide can be increased when it is combined with Estrone.Approved
Etacrynic acidFlurandrenolide may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Flurandrenolide.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Flurandrenolide can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Flurandrenolide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Flurandrenolide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Flurandrenolide.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Flurandrenolide.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Flurandrenolide.Approved
FleroxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Flurandrenolide.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Flumequine.Withdrawn
FluoxymesteroneFlurandrenolide may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Flurandrenolide.Approved, Investigational
FosaprepitantThe serum concentration of Flurandrenolide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Flurandrenolide can be decreased when it is combined with Fosphenytoin.Approved
FurosemideFlurandrenolide may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gallamine Triethiodide.Approved
GatifloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Flurandrenolide can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Flurandrenolide.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Flurandrenolide can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Flurandrenolide.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flurandrenolide.Approved, Investigational
HydrochlorothiazideFlurandrenolide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideFlurandrenolide may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Flurandrenolide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Flurandrenolide.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Flurandrenolide.Approved
IdelalisibThe serum concentration of Flurandrenolide can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Flurandrenolide.Approved
IndapamideFlurandrenolide may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Flurandrenolide can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flurandrenolide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Flurandrenolide.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Flurandrenolide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Flurandrenolide is combined with INGN 225.Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Flurandrenolide.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Flurandrenolide.Withdrawn
ItraconazoleThe serum concentration of Flurandrenolide can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Flurandrenolide.Experimental
KetoconazoleThe serum concentration of Flurandrenolide can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Flurandrenolide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Flurandrenolide.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Flurandrenolide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Flurandrenolide.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of Flurandrenolide can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Flurandrenolide.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Flurandrenolide.Approved
LumacaftorThe serum concentration of Flurandrenolide can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Flurandrenolide.Approved, Investigational
MagaldrateThe bioavailability of Flurandrenolide can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium carbonate.Approved
Magnesium HydroxideThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flurandrenolide.Approved
Magnesium TrisilicateThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flurandrenolide.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flurandrenolide.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Flurandrenolide.Approved
MefloquineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Flurandrenolide.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flurandrenolide.Approved
MestranolThe serum concentration of Flurandrenolide can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Flurandrenolide.Withdrawn
MethallenestrilThe serum concentration of Flurandrenolide can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideFlurandrenolide may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneFlurandrenolide may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneFlurandrenolide may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Flurandrenolide can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Minaprine.Approved
MitotaneThe serum concentration of Flurandrenolide can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Flurandrenolide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Flurandrenolide.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flurandrenolide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flurandrenolide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Flurandrenolide.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Flurandrenolide.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Flurandrenolide.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Flurandrenolide.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Flurandrenolide.Investigational
NefazodoneThe serum concentration of Flurandrenolide can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Flurandrenolide can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Flurandrenolide.Approved
NevirapineThe serum concentration of Flurandrenolide can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Flurandrenolide.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flurandrenolide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Flurandrenolide.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flurandrenolide.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Flurandrenolide.Approved
OxandroloneFlurandrenolide may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Flurandrenolide.Approved
OxymetholoneFlurandrenolide may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flurandrenolide.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Flurandrenolide.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Flurandrenolide can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Flurandrenolide can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Flurandrenolide.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Flurandrenolide.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Flurandrenolide.Approved, Investigational
PhenytoinThe serum concentration of Flurandrenolide can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flurandrenolide.Approved, Investigational
PiretanideFlurandrenolide may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Flurandrenolide.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flurandrenolide.Approved, Investigational
PolythiazideFlurandrenolide may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Flurandrenolide can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of Flurandrenolide can be decreased when it is combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Flurandrenolide can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Flurandrenolide.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Flurandrenolide.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Flurandrenolide can be increased when it is combined with Quinestrol.Approved
QuinethazoneFlurandrenolide may increase the hypokalemic activities of Quinethazone.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Flurandrenolide.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flurandrenolide.Experimental, Investigational
RifabutinThe serum concentration of Flurandrenolide can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Flurandrenolide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Flurandrenolide can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with CDX-110.Investigational
RitonavirThe serum concentration of Flurandrenolide can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Flurandrenolide.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rosoxacin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Flurandrenolide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Flurandrenolide.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Flurandrenolide.Approved
SaquinavirThe serum concentration of Flurandrenolide can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Flurandrenolide can be increased when it is combined with Secoisolariciresinol.Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Flurandrenolide is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Flurandrenolide.Investigational
St. John's WortThe serum concentration of Flurandrenolide can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololFlurandrenolide may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flurandrenolide.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Flurandrenolide.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Flurandrenolide.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Flurandrenolide can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Flurandrenolide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Flurandrenolide.Withdrawn
TelithromycinThe serum concentration of Flurandrenolide can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Flurandrenolide.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Flurandrenolide.Approved
TestosteroneFlurandrenolide may increase the fluid retaining activities of Testosterone.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Flurandrenolide.Approved
TiboloneThe serum concentration of Flurandrenolide can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Flurandrenolide.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flurandrenolide.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flurandrenolide.Approved
TorasemideFlurandrenolide may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Flurandrenolide.Approved, Investigational
TrichlormethiazideFlurandrenolide may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Flurandrenolide.Investigational, Withdrawn
VoriconazoleThe serum concentration of Flurandrenolide can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinFlurandrenolide may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flurandrenolide.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Flurandrenolide.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Flurandrenolide.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Casas-Campillo, C.; U.S. Patent 3,119,748; January 28, 1964; assigned to Syntex Corporation, Panama. Ringold, H.J., Zderic, J.A., Djerassi, C. and Bowers, A.; U.S. Patent 3,126,375; March 24, 1964; assigned to Syntex Corporation, Panama.

General ReferencesNot Available
External Links
ATC CodesD07AC07 — FludroxycortideD07CC03 — Fludroxycortide and antibiotics
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentAnorexic / Cachexia / Obese experiencing rapid weight loss1
Pharmacoeconomics
Manufacturers
  • Watson pharmaceuticals inc
  • Watson laboratories inc
  • Alpharma us pharmaceuticals division
Packagers
Dosage forms
FormRouteStrength
CreamTopical.5 mg/g
LotionTopical.5 mg/mL
OintmentTopical.5 mg/g
TapeTopical4 ug/cm2
TapeTopical4 mcg
Prices
Unit descriptionCostUnit
Cordran (80 X 3 Inch) Box Box105.02USD box
Cordran 4 mcg/sqcm Tape (24 X 3 Inch) Box53.63USD box
Cordran 0.05% lotion4.8USD ml
Cordran sp 0.05% cream4.8USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)251 °CPhysProp
water solubilityInsolubleNot Available
logP0.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0578 mg/mLALOGPS
logP2.02ALOGPS
logP1.56ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.73ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity110.79 m3·mol-1ChemAxon
Polarizability45.74 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9796
Blood Brain Barrier+0.9739
Caco-2 permeable+0.5279
P-glycoprotein substrateSubstrate0.8046
P-glycoprotein inhibitor INon-inhibitor0.6488
P-glycoprotein inhibitor IINon-inhibitor0.7127
Renal organic cation transporterNon-inhibitor0.7839
CYP450 2C9 substrateNon-substrate0.862
CYP450 2D6 substrateNon-substrate0.8911
CYP450 3A4 substrateSubstrate0.7258
CYP450 1A2 substrateNon-inhibitor0.9294
CYP450 2C9 inhibitorNon-inhibitor0.9269
CYP450 2D6 inhibitorNon-inhibitor0.9481
CYP450 2C19 inhibitorNon-inhibitor0.9398
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9098
Ames testNon AMES toxic0.8398
CarcinogenicityNon-carcinogens0.934
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.2002 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9652
hERG inhibition (predictor II)Non-inhibitor0.5679
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-001s-3961000000-a326b0165af296ecf245View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative ParentsGluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-4-steroids / Halogenated steroids / Delta-4-steroids / Ketals / Cyclohexenones / 1,3-dioxolanes / Alpha-hydroxy ketones
SubstituentsProgestogin-skeleton / 21-hydroxysteroid / Pregnane-skeleton / 20-oxosteroid / 3-oxo-delta-4-steroid / 3-oxosteroid / 6-halo-steroid / Halo-steroid / 11-hydroxysteroid / 11-beta-hydroxysteroid
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Baschant U, Tuckermann J: The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol. 2010 May 31;120(2-3):69-75. doi: 10.1016/j.jsbmb.2010.03.058. Epub 2010 Mar 24. [PubMed:20346397 ]
  2. Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG: Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med. 2006 Jan;36(1):37-43. Epub 2005 Oct 28. [PubMed:16255837 ]
  3. Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Emptoz-Bonneton A, Cousin P, Seguchi K, Avvakumov GV, Bully C, Hammond GL, Pugeat M: Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000 Jan;85(1):361-7. [PubMed:10634411 ]
  4. Smith CL, Power SG, Hammond GL: A Leu----His substitution at residue 93 in human corticosteroid binding globulin results in reduced affinity for cortisol. J Steroid Biochem Mol Biol. 1992 Aug;42(7):671-6. [PubMed:1504007 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:53